NASDAQ:NPSP - Shire-Nps Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market Capitalization$4.99 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Shire-Nps Pharmaceuticals logoNPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company's primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company's second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.

Receive NPSP News and Ratings via Email

Sign-up to receive the latest news and ratings for NPSP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:NPSP
CUSIP62936P10
Phone+1-908-4505300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-2.96%
Return on Equity-5.98%
Return on Assets-2.77%

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$4.99 billion

Shire-Nps Pharmaceuticals (NASDAQ:NPSP) Frequently Asked Questions

What is Shire-Nps Pharmaceuticals' stock symbol?

Shire-Nps Pharmaceuticals trades on the NASDAQ under the ticker symbol "NPSP."

How were Shire-Nps Pharmaceuticals' earnings last quarter?

Shire-Nps Pharmaceuticals Inc (NASDAQ:NPSP) posted its quarterly earnings data on Wednesday, February, 18th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by $0.08. The biopharmaceutical company earned $66.70 million during the quarter, compared to analysts' expectations of $69.30 million. Shire-Nps Pharmaceuticals had a negative return on equity of 5.98% and a negative net margin of 2.96%. View Shire-Nps Pharmaceuticals' Earnings History.

How do I buy shares of Shire-Nps Pharmaceuticals?

Shares of NPSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How big of a company is Shire-Nps Pharmaceuticals?

Shire-Nps Pharmaceuticals has a market capitalization of $4.99 billion.

What is Shire-Nps Pharmaceuticals' official website?

The official website for Shire-Nps Pharmaceuticals is http://www.npsp.com.

How can I contact Shire-Nps Pharmaceuticals?

Shire-Nps Pharmaceuticals' mailing address is 550 Hills Dr, BEDMINSTER, NJ 07921-1537, United States. The biopharmaceutical company can be reached via phone at +1-908-4505300.


MarketBeat Community Rating for Shire-Nps Pharmaceuticals (NASDAQ NPSP)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  399
MarketBeat's community ratings are surveys of what our community members think about Shire-Nps Pharmaceuticals and other stocks. Vote "Outperform" if you believe NPSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NPSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/25/2018 by MarketBeat.com Staff

Featured Article: Stock Symbol

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel